15 articles about Lipidor
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
Lipidor updates on Phase III study of AKP02 in treatment of psoriasis - half of patients now recruited
Lipidor AB announces that half of the patients have now been enrolled in the Phase III study of AKP02 skin spray for mild to moderate psoriasis, with the last patient expected to begin treatment in June 2022.
Emollivet, a subsidiary of Lipidor AB, is now launching Emollivet COMBI: an antiseptic emollient spray for horses with pastern dermatitis.
Lipidor Announces Enrolment of First Patients in a Phase III Study on AKP02 for Treatment of Psoriasis
Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today reports that the first patients have been enrolled in a Phase III clinical study using AKP02 cutaneous spray (calcipotriol + betamethasone dipropionate 0.005 %/0.05 %) against mild to moderate psoriasis.
Lipidor expands clinical program, announces investment in new drug development project against acne vulgaris
Lipidor AB announces that it has initiated a preclinical program for a new drug candidate, AKP-08, focused on acne vulgaris.
Lipidor announces approval to start Phase III clinical study of drug candidate AKP02 for treatment of psoriasis
Lipidor AB announced that the company's Phase III clinical study of its drug candidate AKP02 for the treatment of psoriasis has been approved by the Indian Medical Products Agency and is ready to start.
Sweden's innovation authority Vinnova is investing in Lipidor's subsidiary Emollivet. The funding from Vinnova is for SEK 300,000 and will be used for a project in which Emollivet, through interaction with animal owners and others in the animal health market, will gather data for the upcoming launch.
Lipidor - update on the company's phase III clinical trial of drug candidate AKP02 for treatment of psoriasis
Lipidor AB provides an update on the planned Phase III study of the company's drug candidate AKP02 for the treatment of psoriasis.
Lipidor signs cooperation agreement with contract manufacturer to offer licensees the opportunity for GMP production
Lipidor AB announced that the Company has signed a new cooperation agreement with Aurena Laboratories AB. Over a five-year period, Lipidor will invest up to SEK 15 million in the new collaboration.
Lipidor Signs Agreement With CRO for Implementation of Phase III Clinical Study of Drug Candidate AKP-02 Against Psoriasis
Lipidor AB announced an agreement with Cadila Pharmaceuticals, a leading Indian pharmaceutical company with extensive CRO capacity, to conduct a Phase III study for Lipidor's drug candidate AKP-02.
Lipidor AB (publ) Formalizes Relationship With Subsidiary Emollivet AB Through License Agreement and Proposes Financing of Subsidiary
Lipidor AB ("Lipidor" or the "Company") and its subsidiary Emollivet AB ("Emollivet") have formalized the relationship by entering into a licence agreement that regulates the right to Lipidor's patented AKVANO® technology
In light of the company's successful Phase III study of calcipotriol spray against mild to moderate plaque psoriasis and subsequent discussions with pharmaceutical companies, the Board of Lipidor submits an updated project plan together with prioritization of the company's project portfolio.
In connection with the ongoing outbreak of Covid-19, caused by the new coronavirus, demand for disinfectants has snowballed and many products have suffered from supply shortages.
Lipidor And Cadila Pharmaceuticals Announce Agreement On Phase III Clinical Study And Joint Commercialization Of Topical Psoriasis Product